Navigation Links
Drug Sorafenib Improves Kidney Cancer Outcomes
Date:10/9/2008

It helped older and younger patients, study says

THURSDAY, Oct. 9 (HealthDay News) -- People with kidney cancer, regardless of age, seem to benefit from and tolerate sorafenib drug therapy equally well, a new study says.

The finding, published online Oct. 7 in the Journal of the National Cancer Institute, counters the general perception that older patients derive less benefit from the therapy and are more likely to suffer side effects than younger patients.

The study, conducted by Tim Eisen of Addenbrooke's Hospital and the University of Cambridge in the United Kingdom and colleagues, found patients age 70 and older and those 69 and younger had similar responses to the drug in terms of self-reported health deterioration and improved quality of life over that time.

"Sorafenib treatment appeared to improve outcomes among patients with advanced renal cell carcinoma, regardless of age," the authors wrote. "Additionally, side effects were expected, mild, and medically manageable. There was no notable difference in the frequency or severity of sorafenib-related toxicity between younger and older patients."

The groups also had similar median progression-free survival times with young patients going almost 24 weeks and older ones just passing 26 weeks. The percentage of older patients who had a complete or partial response to the treatment or had the disease stabilize was 84.3 percent compared with 83.5 percent for the younger patients.

More information

The U.S. National Cancer Institute has more about kidney and renal cancer.



-- Kevin McKeever



SOURCE: Journal of the National Cancer Institute, news release, Oct. 7, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Page: 1

Related medicine news :

1. Sorafenib Slows Growth of Some Leukemias
2. Analysis shows combining sorafenib with carboplatin/paclitaxel adds no benefit in lung cancer
3. Sorafenib Shows Promise for Heart-Lung Disease
4. Study Demonstrates Marteks Algal DHA Oil Improves Blood Triglyceride Lipid Levels
5. Exercise and yoga improves quality of life in women with early-stage breast cancer
6. Enhanced PrecyseCode 2X(TM) Further Accelerates Remote Coding and Improves Cash Flow for Hospitals
7. Weight-based dosing of ribavirin improves outcomes for patients with hepatitis C
8. Kerry Extends, Improves Small Business Innovation Program
9. Thalidomide Improves Outcomes for Older Myeloma Patients
10. Grape Consumption Improves Antioxidant Capacity in Humans
11. JCSM: CPAP therapy improves symptoms of depression in OSA patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... As pharmaceutical companies are held ... with process innovation in drug formulation and manufacturing. CoreRx offers its clients ... equipment in support of their development and manufacturing goals. , The company ...
(Date:4/25/2017)... ... April 25, 2017 , ... Back Pain Centers ... back pain with a reputable physician in their area, announces the launch of a ... information for patients who are looking for reputable physicians to help them with back ...
(Date:4/25/2017)... ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed to providing the highest ... chronic problems, I focus on preventative care with all my patients to alleviate possible future ... always feel free to contact my office and my trained staff will assist you in ...
(Date:4/25/2017)... ... April 25, 2017 , ... Emergency Physician and Distinguished Professor of Emergency ... Series, Outliers in Writing, set to publish in summer 2017. , Dr. Bobrow, ... University of Arizona College of Medicine. He also serves as Medical Director for the ...
(Date:4/25/2017)... ... ... Vetoquinol USA® , a world-class developer of veterinarian-approved ... EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in Lexington. Flexadin UCII ... The scientifically-developed Flexadin UCII supports the body’s normal repair of cartilage and joints. ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: ... that address significant unmet medical needs, today announced ... Company,s consumer product development program, based on its ... for Investigative Dermatology (SID) 76 th Annual ... promote the sciences relevant to skin health and ...
(Date:4/20/2017)... 2017  AbbVie (NYSE: ABBV), a global biopharmaceutical ... chronic hepatitis C virus (HCV) infected patients with ... compensated cirrhosis (Child-Pugh A) achieved sustained virologic response ... its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These ... 12 weeks of G/P treatment without ribavirin. Patients ...
(Date:4/20/2017)... Research and Markets has announced the addition of ... By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, Argentina, ... to their offering. ... The Latin American pharmaceutical contract manufacturing services market is anticipated ... drug registration cost in Latin American countries and continuous economic ...
Breaking Medicine Technology: